白蛋白结合修饰改善药代动力学的放射性碘标记FR-β靶向示踪剂用于AS和NAFL巨噬细胞显像
本研究开发了两种放射性碘标记的FR-β靶向SPECT示踪剂[131I]IPBF和[131I]IBF,用于无创检测动脉粥样硬化斑块和非酒精性脂肪肝。在正常小鼠中[131I]IPBF的血浆消除半衰期(8.14 h)显著长于[131I]IBF(2.95 h),且对Raw 264.7细胞的Kd值分别为43.94 ± 9.83 nM和61.69 ± 15.19 nM。ApoE-/-小鼠SPECT/CT显像显示[131I]IPBF在进展期斑块和NAFL中高摄取,离体放射自显影证实其在高危AS斑块中的特异性摄取。
要点
- [131I]IPBF经白蛋白结合修饰后血浆半衰期延长至8.14 h,优于[131I]IBF的2.95 h。
- [131I]IPBF对活化巨噬细胞FR-β具有特异性摄取,Kd值为43.94 ± 9.83 nM。
- SPECT/CT显像显示[131I]IPBF在ApoE-/-小鼠进展期AS斑块和NAFL中高摄取。
核心结论
- [131I]IPBF是一种经白蛋白结合修饰的FR-β靶向示踪剂,具有延长的血浆半衰期,有望用于AS斑块及伴随脂肪肝的监测。
研究设计与样本
- 研究开发了[131I]IPBF和[131I]IBF两种放射性碘标记探针,进行细胞摄取研究、正常小鼠体内分布、ApoE-/-小鼠HFHC饮食诱导AS模型、体外Kd值测定及SPECT/CT显像与组织学比较。
主要发现
- 两种探针放射化学纯度均>95%,摩尔活度高达3 MBq/nmol。
- [131I]IPBF在正常小鼠的血浆消除半衰期t1/2z为8.14 h,显著长于[131I]IBF的2.95 h。
- [131I]IPBF和[131I]IBF在Raw 264.7细胞中的Kd值分别为43.94 ± 9.83 nM和61.69 ± 15.19 nM。
- SPECT显像显示[131I]IPBF在进展期斑块和NAFL中高摄取,离体放射自显影证实其在高危AS斑块中的特异性摄取。
临床怎么用
- 该探针尚处于概念验证阶段,暂未提供临床使用推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The formation of advanced plaques, which is characterized by the uninterrupted aggregation of macrophages with high expression of folate receptor-β (FR-β), is observed in several concomitant metabolic syndromes. The objective of this study was to develop a novel FR-β-targeted single-photon emission computed tomography (SPECT) radiotracer and validate its application to the noninvasive detection of atherosclerosis (AS) plaque and non-alcoholic fatty liver (NAFL). METHODS: Two radioiodinated probes, [131I]IPBF and [131I]IBF, were developed, and cell uptake studies were used to identify their specific targets for activated macrophages. Biodistribution in normal mice was performed to obtain the pharmacokinetic information of the probes. Apolipoprotein E knockout (ApoE-/-) mice with atherosclerotic aortas were induced by a high-fat and high-cholesterol (HFHC) diet. To investigate the affinity of radiotracers to FR-β, Kd values were determined using in vitro assays. In addition, the assessments of the aorta in the ApoE-/- mice at different stages were performed using in vivo SPECT/CT imaging, and the findings were compared by histology. RESULTS: Both [131I]IPBF and [131I]IBF were synthesized with > 95% radiochemical purity and up to 3 MBq/nmol molar activity. In vitro assay of [131I]IPBF showed a moderate binding affinity to plasma proteins and specific uptake in activated macrophages. The prolonged blood elimination half-life (t1/2z) of [131I]IPBF (8.14 h) was observed in a pharmacokinetic study of normal mice, which was significantly longer than that of [131I]IBF (t1/2z = 2.95 h). As expected, the Kd values of [131I]IPBF and [131I]IBF in the Raw 264.7 cells were 43.94 ± 9.83 nM and 61.69 ± 15.19 nM, respectively. SPECT imaging with [131I]IPBF showed a high uptake in advanced plaques and NAFL. Radioactivity in excised aortas examined by ex vivo autoradiography further confirmed the specific uptake of [131I]IPBF in high-risk AS plaques. CONCLUSIONS: In summary, we reported a proof-of-concept study of an albumin-binding folate derivative for macrophage imaging. The FR-β-targeted probe, [131I]IPBF, significantly prolongs the plasma elimination half-life and has the potential for the monitoring of AS plaques and concomitant fatty liver.
引用
- Wen X, Shi C, Yang L, et al. A radioiodinated FR-β-targeted tracer with improved pharmacokinetics through modification with an albumin binder for imaging of macrophages in AS and NAFL. Eur J Nucl Med Mol Imaging. 2021. PMID: 34155537. doi:10.1007/s00259-021-05447-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。